CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 506 enrolled
Drug / intervention
Lansoprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01135368
NCT01135368Phase 4Completed
CompareCT.gov

Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study

Takeda·interventional·Posted Jun 2, 2010·Updated Sep 3, 2012

In Brief

A Phase 4 clinical trial evaluating Lansoprazole for Gastroesophageal Reflux. Completed, enrolled 506 participants.

Detailed Summary

The purpose of this study is to measure the safety, efficacy and quality of life of lansoprazole in patients with reflux disease over a five year period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2, 2010
Enrollment StartJun 1, 2002
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 16.1 years ago

Interventions

Lansoprazoledrug

Lansoprazole capsules